Bausch & Lomb (BLCO) Q2 2026 Earnings
How Did BLCO Stock React to Q2 2026 Earnings?
S&P 500 over the same 30 days: +5.47%.
Did BLCO Beat Earnings? Q2 2026 Results
No. Bausch & Lomb reported Q2 2026 earnings of $0.15 a share on Jul 29, 2026, missing the $0.16 consensus estimate by 6.5%. Revenue was $1.4B against a $1.4B estimate.
Bausch & Lomb delivered a mixed second quarter for fiscal 2026, posting revenue of $1.39 billion, up 9.1% year over year and edging past the $1.37 billion consensus estimate by 1.88%, while adjusted EPS of $0.15 fell just short of the $0.16 consensus by 6.48%. The headline story, however, was the breadth of operational improvement underneath those numbers: the company swung to GAAP operating income of $83 million from an operating loss of $11 million a year ago, and cash flow from operations surged to $153 million from $35 million. The Surgical segment led the way, with its premium intraocular lens portfolio growing 175% and lifting total Surgical revenue by 19%, while the Pharmaceuticals segment benefited from 27% combined first-half growth in MIEBO and XIIDRA. On the back of that momentum, management raised its full-year 2026 revenue guidance to $5.44 billion to $5.54 billion and nudged adjusted EBITDA higher, though the outlook notably excludes any potential tariff policy impacts, a caveat that underscores the uncertain macro backdrop the company continues to navigate.
- 175% reported revenue growth in premium IOLs, now 13% of total Surgical revenue vs 6% in 2025
- MIEBO and XIIDRA delivered 27% combined revenue growth in H1 2026 vs H1 2025
- Growth in daily SiHy, Biotrue ONEday and ULTRA monthly contact lenses
- Over-the-counter dry eye product sales growth
- Growth in international pharmaceuticals
- Operating efficiencies contributing to margin expansion
“Broad-based revenue growth, leverage in the P&L, margin expansion and conversion to cash flow. These have been themes since we unveiled our three-year plan for growth at Investor Day last November, and in the second quarter progress continued at an accelerated pace.”
Bausch & Lomb CEO, on the earnings call
What Is Bausch & Lomb's Outlook?
Bausch + Lomb raised its full-year 2026 guidance. Revenue is now expected at $5.440B–$5.540B (previously $5.420B–$5.520B), representing 5.8%–7.7% constant currency growth (up from 5.3%–7.2%). Adjusted EBITDA excluding acquired IPR&D is now expected at $1.025B–$1.075B (previously $1.010B–$1.060B). Full-year revenue foreign exchange tailwinds are estimated at $45M (previously $50M). The guidance increase reflects continued strong Q2 business performance and anticipated stronger performance for the remainder of 2026, partially offset by moderating currency tailwinds. Guidance does not take into consideration any changes in tariff policy.
BLCO YoY Financials
| Metric | Q2 2026 | Q2 2025 | Year over year |
|---|---|---|---|
| Revenue | $1.4B | $1.3B | +9.1% |
| Gross Profit | $867.0M | $753.0M | +15.1% |
| Operating Income | $83.0M | $8.7M | +854.6% |
| Net Income | −$14.0M | −$7.9M | +77.4% |
BLCO Revenue by Segment
When Does Bausch & Lomb Report Next?
Figures from SEC filings and company reports. Not investment advice.